Literature DB >> 2615290

Uricosuric effect of irtemazole in healthy subjects.

U Gresser1, N Zöllner.   

Abstract

Following a single dose of 50 mg irtemazole per os, plasma uric acid levels decreased after 1 h and fell to 53.5% of the original value within 6-12 h. Renal uric acid excretion increased up to 66 mg/h 30 min after drug application and reached its maximum of 151 mg/h 30 min later. Uric acid clearance also increased after 30 min and reached its maximum of 56 ml/min after 60 min. The response of the kidney to irtemazole is faster than to benzbromarone or probenecid. Lowering of plasma uric acid has a shorter-lasting effect than benzbromarone or probenecid. At 24 h after the application of 50 mg irtemazole the decrease of the plasma uric acid was between 15.4% and 30.0%, or 24.7% on average. Three days after the application the basic plasma uric acid levels were reached again.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2615290     DOI: 10.1007/bf01716059

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  13 in total

1.  Uricosuric agents.

Authors:  G M Fanelli
Journal:  Arthritis Rheum       Date:  1975 Nov-Dec

2.  Enzymatic determination of uric acid; with detailed directions.

Authors:  E PRAETORIUS; H POULSEN
Journal:  Scand J Clin Lab Invest       Date:  1953       Impact factor: 1.713

3.  Effect of single oral doses of benzbromarone on serum and urinary uric acid.

Authors:  A K Jain; J R Ryan; F G McMahon; R J Noveck
Journal:  Arthritis Rheum       Date:  1974 Mar-Apr

4.  [Effect of benzbromaronum on the renal uric acid excretion in healthy persons].

Authors:  N Zöllner; W Dofel; W Gröbner
Journal:  Klin Wochenschr       Date:  1970-04-01

5.  [Uricosuric agents].

Authors:  N Zöllner; W Gröbner
Journal:  Arzneimittelforschung       Date:  1971-10

6.  Clinical evaluation of benzbromarone: a new uricosuric drug.

Authors:  L B Sorensen; D J Levinson
Journal:  Arthritis Rheum       Date:  1976 Mar-Apr

7.  Myoadenylate deaminase deficiency: successful symptomatic therapy by high dose oral administration of ribose.

Authors:  N Zöllner; S Reiter; M Gross; D Pongratz; C D Reimers; K Gerbitz; I Paetzke; T Deufel; G Hübner
Journal:  Klin Wochenschr       Date:  1986-12-15

8.  Pharmacokinetic and clinical studies of a new uricosuric agent - benzbromarone.

Authors:  T F Yu
Journal:  J Rheumatol       Date:  1976-09       Impact factor: 4.666

Review 9.  Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-11       Impact factor: 9.546

Review 10.  Clinical pharmacokinetics of probenecid.

Authors:  R F Cunningham; Z H Israili; P G Dayton
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447

View more
  2 in total

1.  Rapid onset of uricosuria after oral administration of irtemazole, an uricosuric substance.

Authors:  U Gresser; U Kronawitter; O Adjan; N Zöllner
Journal:  Klin Wochenschr       Date:  1989-10-17

2.  Uricosuric effect of different doses of irtemazole in normouricaemic subjects.

Authors:  U Gresser; I Kamilli; U Kronawitter; N Zöllner
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.